New York / London, August 12, 2026 — The global clinical nutrition market is estimated at US$ 15.48 billion in 2024 and is projected to reach US$ 25.94 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.3%. Note: The source report also states a 2025 value of USD 16.30 billion rising to USD 28.76 billion by 2036 at the same 5.3% CAGR (adding USD 11.60 billion in absolute value from 2026 to 2036); figures below prioritize the primary 2024–2034 outlook while flagging variances.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=10421

Key Findings

• Global market valued at US$ 15.48 billion in 2024; forecast US$ 25.94 billion in 2034 at 5.3% CAGR.
• North America expected to hold 24.3% of global market share by 2034.
• East Asia market value projected at US$ 5.99 billion by 2034.
• Parenteral nutrition segment: US$ 9.35 billion in 2024, rising to US$ 15.88 billion by 2034 at 5.4% CAGR (alternate summary figures: USD 9.85 billion in 2025 to USD 17.64 billion by 2036 at 5.4% CAGR).
• Infant nutrition segment value: US$ 10.07 billion by 2034 (alternate: forecast to reach USD 11.17 billion by 2036).
• Metabolic disorders application: US$ 3.44 billion in 2024, to US$ 5.81 billion by 2034 at 5.4% CAGR (alternate: to USD 6.45 billion by 2036 at 5.4% CAGR).
• Cancer segment projected to account for 21.9% of global market revenue by 2034.
• Hospitalized patient malnutrition frequency ranges from 20% to 50% (NCBI study, February 2022).

Growth Drivers

• Rising prevalence of chronic conditions including diabetes, cardiovascular disease, cancer, osteoporosis, metabolic disorders, Alzheimer’s disease, ADHD, and central nervous system abnormalities.
• CDC data (August 2023): 6 million children aged 3–17 diagnosed with ADHD at some time; Thailand prevalence 4.2%–8.1% (International Journal of Child Development and Mental Health, November 2022).
• Global aging population: WHO projects 426 million adults over age 80 by 2050, increasing demand for clinical nutrition to address malnutrition, sarcopenia, and comorbidity-linked deficiencies.
• Advances in personalized nutrition via nutrigenomics, metabolomics, wearable monitoring, and digital health platforms enabling individualized plans beyond institutional settings.
• Growing demand for functional meals, ready-to-drink beverages, and customized nutrition plans supporting immune, digestive, and cognitive function.

Segment Analysis by Product

• Parenteral nutrition leads and is gaining sales opportunity versus infant nutrition: US$ 9.35 billion (2024E) to US$ 15.88 billion (2034F) at 5.4% CAGR, driven by hospital adoption for patients unable to consume food orally (cancer, gastrointestinal disorders, critical care).
• Infant nutrition: Serves neonatal care, premature infant support, and therapeutic formulas for early-childhood metabolic and neurological conditions; projected US$ 10.07 billion by 2034.

Segment Analysis by Application

• Metabolic disorders is the largest application segment: US$ 3.44 billion in 2024 to US$ 5.81 billion by 2034 at 5.4% CAGR, reflecting diabetes, obesity, and related long-term nutritional management needs.
• Other applications: Cancer (21.9% share by 2034), neurological diseases, gastrointestinal disorders, and others.

Country-Level Growth Comparison

East Asia overall projected at US$ 5.99 billion by 2034.

Competitive Landscape

Key companies profiled include: Danone (Nutricia); Abbott Nutrition; Grifols, S.A.; Pfizer Inc.; Baxter; Meiji Holdings Co., Ltd.; Bayer AG; Fresenius Kabi; Nestlé; AbbVie (Allergan); Mead Johnson & Company, LLC; Baxter International Inc.; Victus, Inc.; Otsuka Holdings Co., Ltd. Additional active players listed: Nestlé, Abbott Nutrition, Danone (Nutricia), Fresenius Kabi, Baxter International, Mead Johnson, Pfizer, Bayer AG, Grifols, Meiji Holdings, Otsuka Holdings, and AbbVie (Allergan).

Recent Developments

• SFI Health introduced EQUAZEN PRO in January 2021 for children and teenagers with ADHD and neurodiverse disorders to support focus, study, and brain function.
• FrieslandCampina Ingredients launched Nutri Whey™ ProHeat, a heat-stable whey protein using microparticulation technology, on November 23, 2023, for the medical nutrition industry.
• Danone purchased Functional Formularies (U.S.-based whole food tube feeding solutions supplier) from Swander Pace Capital in May 2024, expanding enteral tube feeding products under its Renew Strategy.
• Danone India released new Protinex flavors with no added sugar in December 2023, aligned with a pledge to cut sugar by 20% by 2020 under FSSAI’s Eat Right Movement (Protinex trusted for over 60 years).

Restraints

• Unequal distribution of healthcare resources and services, especially in rural regions, limits accessibility of clinical nutrition products in certain countries.
• Cultural preference for traditional systems (e.g., Ayurvedic) in some markets reduces adoption of therapeutic nutrition products.

How to Choose Clinical Nutrition Solutions

Procurement and R&D teams evaluating options should prioritize:

1.     Alignment with primary application needs (e.g., metabolic disorders at US$ 3.44 billion base, or cancer at projected 21.9% share).

2.     Route of administration suitability (parenteral for non-oral patients versus infant-specific formulas).

3.     Evidence of clinical efficacy and regulatory compliance for hospital or home use.

4.     Compatibility with personalized approaches (nutrigenomics, digital monitoring).

5.     Supplier track record on innovation and recent product launches or acquisitions (e.g., heat-stable proteins, tube-feeding expansions).

6.     Geographic availability and infrastructure support matching target country CAGRs and market values.

Report Scope

The Fact.MR report (FACT10421MR, 170 pages, published 26 Mar 2026) analyzes the clinical nutrition market by product (infant nutrition, parenteral nutrition), application (cancer, metabolic disorders, neurological diseases, gastrointestinal disorders, others), and region (North America, Western Europe, Eastern Europe, Latin America, East Asia, South Asia & Pacific, Middle East & Africa), covering 30+ countries including the US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, and Korea. Forecast periods referenced include 2024–2034 and 2026–2036.

Explore More Related Studies Published by Fact.MR Research

Olive Stone Coffee and Beverage Roasts Market- https://www.openpr.com/news/4600091/starbucks-and-nestle-drive-u-s-share-as-global-olive-stone

Texture Recovery Hydrocolloids Market- https://www.openpr.com/news/4600093/cargill-anchors-u-s-texture-recovery-hydrocolloids-demand-as

Heat Stable Plant Protein Texturizing Agents Market- https://www.openpr.com/news/4600094/adm-advances-heat-stable-plant-protein-agents-as-u-s-demand

Corn Germ Oil Market- https://www.openpr.com/news/4598577/ach-food-companies-holds-8-6-of-corn-germ-oil-market-as-u-s

Fermented Chickpea Protein Concentrates Market- https://www.openpr.com/news/4598580/ingredion-steadies-u-s-fermented-chickpea-protein

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

 - Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

 Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination